RxDoctor Payments Data

David Lewis, MD

Family Medicine · Philadelphia, PANPI 1679554109

Payments from drug & device makers

$1,547in general payments, 2019–2025

Across 95 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$416
  • Novo Nordisk$237
  • Gilead$222
  • Lilly USA, LLC$149
  • AbbVie$64
  • Exact Sciences$50
  • plus $410 from 16 others

What the payments were for

  • Food & beverage$1,541100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,547 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$63,990
Medicare patients
177
Services billed
1,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide16$34,117
OzempicSemaglutide18$30,001
JardianceEmpagliflozin19$25,525
MounjaroTirzepatide14$21,960
JanuviaSitagliptin Phosphate18$19,582
FarxigaDapagliflozin Propanediol18$16,810
XareltoRivaroxaban13$16,732
Tresiba Flextouch U-100Insulin Degludec22$14,084
EliquisApixaban18$13,577
SynjardyEmpagliflozin/Metformin Hcl11$6,379
Breo ElliptaFluticasone/Vilanterol12$5,398
Atorvastatin Calcium313$4,717
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,687
Nano 2nd Gen Pen NeedlePen Needle, Diabetic32$2,647
Nifedipine ErNifedipine49$2,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$149$56,07730 claims
Boehringer IngelheimJardiance, Synjardy$18$31,90530 claims
Novo NordiskOzempic$237$30,00118 claims
MerckJanuvia$45$19,58218 claims
AstraZenecaFarxiga$416$16,81018 claims
Johnson & JohnsonXarelto$18$16,73213 claims
PfizerEliquis$14$13,57718 claims
GSKBreo Ellipta$41$5,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →